STOCK TITAN
  1. Home
  2. News
  3. SABSW

SAB Biotherapeutics Inc - SABSW STOCK NEWS

Welcome to our dedicated news page for SAB Biotherapeutics (Ticker: SABSW), a resource for investors and traders seeking the latest updates and insights on SAB Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SAB Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SAB Biotherapeutics's position in the market.

News
SAB Biotherapeutics Provides SAB-142 Trial Update
Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) provides an update on the SAB-142 trial, reporting completion of dosing the third cohort with no observation of serum sickness. The Phase 1 clinical trial aims to investigate safety, tolerability, pharmacokinetics, and immunogenicity of SAB-142, a human anti-thymocyte immunoglobulin for delaying the onset or progression of type 1 diabetes (T1D).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
none
-
News
SAB Biotherapeutics to Present at INNODIA Annual Meeting
Rhea-AI Summary
SAB Biotherapeutics, Inc. announced their Chief Medical Officer will share details on the SAB-142 clinical development plan at the INNODIA Annual Meeting. SAB is developing hIgG for delaying T1D onset or progression, positioning them as a key partner in the global T1D landscape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
conferences
-
News
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced CEO Samuel J. Reich will present at the 23rd Annual Needham Virtual Conference to discuss the company's hIgG therapy for type 1 diabetes. The presentation will cover SAB-142, a biologic for delaying diabetes onset, and partnership opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences
News
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
Rhea-AI Summary
SAB Biotherapeutics, Inc. (SABS) collaborates with Navy Medical Research Command for a safety study on SAB-176, a therapy for influenza prevention. The study aims to evaluate the safety and tolerability of intramuscular administration of SAB-176, a novel multi-target biologic with sustained neutralization activity against Influenza A and B. The partnership, funded by the Henry Jackson Foundation, utilizes SAB's DiversitAb™ platform to develop fully human polyclonal antibodies. SAB-176 has received Breakthrough Therapy and Fast Track Designations from the FDA. The study marks the first intramuscular administration of a DiversitAb™ platform product, showcasing the potential of SAB's therapeutic products beyond type 1 diabetes treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.91%
Tags
partnership
-
News
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
Rhea-AI Summary
SAB Biotherapeutics, Inc. (SABS) announced Samuel J. Reich will present at the BIO CEO & Investor Conference to discuss the latest developments in their lead clinical program, SAB-142, for delaying Type 1 diabetes onset and progression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
conferences
-
News
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
SAB Biotherapeutics, Inc. (SABS) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference to discuss the latest developments from its lead clinical program, SAB-142, a novel biologic for delaying onset and progression of Type 1 diabetes in adults and children.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
conferences
News
SAB Biotherapeutics Announces Executive Leadership Change
Rhea-AI Summary
SAB Biotherapeutics, Inc. announced the appointment of Samuel J. Reich as the new CEO, effective February 2, 2024. Eddie J. Sullivan, Ph.D., will continue as President and a member of the Board of Directors. The company aims to progress its lead product candidate SAB-142 through milestones towards approval, with a focus on delaying the onset or progression of type 1 diabetes (T1D).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
management
-
News
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
SAB Biotherapeutics, Inc. (SABS) has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) after conducting a 1-for-10 reverse split of its common shares. The Company's common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on January 23, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
-
News
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced a reverse stock split of its outstanding shares of common stock, effective January 5, 2024, to increase per share trading price and maintain Nasdaq listing compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
News
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) has initiated the first-in-man Phase 1 clinical study of SAB-142, a fully-human anti-thymocyte immunoglobulin (ATG) targeting immune cells involved in the destruction of insulin-producing pancreatic beta cells to potentially preserve beta cell function. The company is pursuing IND and CTA filings with U.S. FDA and EMA in 2024 to advance SAB-142 into a Phase 2b study for disease-modification of Type 1 Diabetes (T1D). The Phase 1 trial in Australia aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of SAB-142 in healthy volunteers and participants with T1D, with a focus on establishing Proof of Biological Activity (POBA) for SAB-142.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
clinical trial
Stock SABSW logo
SAB Biotherapeutics Inc

Nasdaq:SABSW

SABSW Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SABSW Stock Data

5.93M
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Sioux Falls

About SABSW

sab biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.